Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study

Background: SARS-CoV-2 variant Beta (B.1.351) was designated as a Variant of Concern (VoC) after becoming the dominant strain in South Africa and spreading internationally. BNT162b2 showed lower levels of neutralizing antibodies against Beta than against other strains raising concerns about effectiv...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shepherd R. Singer, M.D., Frederick J. Angulo, Ph.D., David L. Swerdlow, M.D., John M. McLaughlin, Ph.D., Itay Hazan, M.Sc., Netanel Ginish, B.S, Emilia Anis, M.D., Ella Mendelson, Ph.D., Orna Mor, Ph.D., Neta S Zuckerman, Ph.D., Oran Erster, Ph.D., Jo Southern, Ph.D., Kaijie Pan, M.S., Gabriel Mircus, Ph.D., Marc Lipsitch, D.Phil., Eric J. Haas, M.D., Luis Jodar, Ph.D., Yeheskel Levy, M.D., Sharon Alroy-Preis, M.D.
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
COVID-19
SARS-CoV-2
vaccine effectiveness
prevention
mRNA vaccines
variant Beta (B.1.351)
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/62a9342b69cb4e34bc3842674ef15451
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares